Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of iNKT cells plus CD8+ T cells in pancreatic cancer after first-line treatment failure
ChiCTR1800017831Phase 2Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Oct 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous CD8+ antigen-specific T cells in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: 6-month overall survival rate. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
autologous CD8+ antigen-specific T cells
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1800017831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017831.